Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 321-327

  Saleh, E M ^a   El Awady, R A ^a,b   Anis, N ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

5 fluorouracil; Constant field gel electrophoresis; Drug resistance; Induction of double strand breaks

Indexed keywords

CASPASE 9; FAS LIGAND; FLUOROURACIL; SULFORHODAMINE B;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHEMOSENSITIVITY; COLON CARCINOMA; CONSTANT FIELD GEL ELECTROPHORESIS; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

EID: 84869022290     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.965     Document Type: Article

References (35)

1. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, et al: Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872-877, 2009.
2. Parker WB and Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48: 381-395, 1990.
3. Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ and Johnston PG: The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol 30: 3-9, 2003.
4. An Q, Robins P, Lindahl T and Barnes DE: 5-fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 67: 940-945, 2007.
5. Wang W, Cassidy J, O'Brien V, Ryan KM and Collie-Duguid E: Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 64: 8167-8176, 2004.
6. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
7. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
8. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G and Peters GJ: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5: 643-654, 1999.
9. Grem JL: Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 11: 5067-5068, 2005.
10. Arnold CN, Goel A and Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106: 66-73, 2003.
11. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C and Lesuffleur T: Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98: 498-504, 2002.
12. Liu R, Page C, Beidler DR, Wicha MS and Núñez G: Overexpression of Bclx(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 155: 1861-1867, 1990.
13. Shi X, Liu S, Kleeff J, Friess H and Büchler MW: Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62: 354-362, 2002.
14. Miyashita T: Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
15. Petak I, Tillman DM and Houghton JA: p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Cancer Res 6: 4432-4441, 2000.
16. Zhang N, Yin Y, Xu S and Chen W: Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569, 2008.
17. Iliakis GE, Cicilioni O and Metzger L: Measurement of DNA double-strand breaks in CHO cells at various stages of the cell cycle using pulsed field gel electrophoresis: calibration by means of 1251 decay. Int J Radiat Biol 59: 343-357, 1991.
18. Dahm-Daphi J and Dikomey E: Separation of DNA fragments induced by ionizing irradiation using a graded-field gel electrophoresis. Int J Radiat Biol 67: 161-168, 1995.
19. Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US and Bonner WM: Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany NY) 3: 168-174, 2011.
20. De Angelis PM, Svendsrud DH, Kravik KL and Stokke T: Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5: 20, 2006.
21. El-Awady RA, Saleh EM and Dahm-Daphi J: Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil? Anticancer Drugs 21: 277-287, 2010.
22. El-Awady RA, Dikomey E and Dahm-Daphi J: Radiosensitivity of human tumour cells is correlated with the induction but not with the repair of the DNA double-strand breaks. Br J Cancer 89: 593-601, 2003.
23. Saleh EM, El-Awady RA, Abdel Alim MA and Abdel Wahab AA: Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys 55: 95-105, 2009.
24. El-Awady RA, Ali MM, Saleh EM and Ghaleb FM: Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition. Saudi Med J 29: 558-564, 2008.
25. Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, et al: 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers 2: 1717-1730, 2010.
26. Pettersen HS, Visnes T, Vågbø CB, Svaasand EK, Doseth B, Slupphaug G, Kavli B and Krokan HE: UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 39: 8430-8444, 2011.
27. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH and Punt CJ: A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 45: 1935-1949, 2009.
28. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al: Micro RNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog2 (hMSH2). Proc Natl Acad Sci USA 107: 21098-21103, 2010.
29. Pino MS and Chung DC: Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 5: 385-399, 2011.
30. Sinicrope FA and Yang ZJ: Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol 7: 467-474, 2011.
31. Xiao Z, Xue J, Sowin TJ, Rosenberg SH and Zhang H: A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24: 1403-1411, 2005.
32. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204, 2008.
33. Bartek J, Lukas C and Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792-804, 2004.
34. Adamsen BL, Kravik KL and De Angelis PM: DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. Int J Oncol 39: 673-682, 2011.
35. Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R and Boothman DA: DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 158: 679-692, 2009.